Yarbrough Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Yarbrough Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,100	Closed	-$921K	–	171
2025 Q2	$921K	Hold	11,100	–	–	0.03%	100
2025 Q1	$900K	Sell	11,100 -26,240	-70%	-$2.35M	0.04%	99
2024 Q4	$3.36M	Hold	37,340	–	–	0.13%	62
2024 Q3	$3.69M	Hold	37,340	–	–	0.15%	59
2024 Q2	$3.46M	Hold	37,340	–	–	0.14%	57
2024 Q1	$3.54M	Hold	37,340	–	–	0.15%	59
2023 Q4	$3.33M	Hold	37,340	–	–	0.17%	61
2023 Q3	$2.73M	Hold	37,340	–	–	0.16%	63
2023 Q2	$3.11M	Hold	37,340	–	–	0.18%	65
2023 Q1	$2.85M	Buy	37,340 +13,200	+55%	+$1.1M	0.23%	65
2022 Q4	$2M	Buy	24,140 +13,030	+117%	+$1.05M	0.16%	64
2022 Q3	$881K	Hold	11,110	–	–	0.07%	89
2022 Q2	$825K	Buy	+11,110	New	+$834K	0.06%	86

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Yarbrough Capital's XBI Position: Q3 2025 in Review

Yarbrough Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 11,100 shares — an estimated $921K sold.

Yarbrough Capital first reported a position in XBI in Q2 2022 and held it in 13 quarters. The position peaked at $3.69M in Q3 2024. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Yarbrough Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Yarbrough Capital sold 11,100 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $921K.
Yarbrough Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 13 quarters.
Yarbrough Capital's State Street SPDR S&P Biotech ETF position peaked at $3.69M in Q3 2024.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Yarbrough Capital's 13F filing for Q3 2025, filed 20 Oct 2025.